Outcomes of RVD and RVDD regimens*
| . | Response after 4 cycles, % . | Response after 8 cycles, % . | Estimated PFS at 18 months, % . | ||||
|---|---|---|---|---|---|---|---|
| ≥ PR . | ≥ VGPR . | CR/nCR . | ≥ PR . | ≥ VGPR . | CR/nCR . | ||
| RVD6 | 75 | 11 | 6 | 96 | 53 | 23 | 75 |
| RVDD | 96 | 57 | 29 | 95 | 65 | 35 | 82 |
| . | Response after 4 cycles, % . | Response after 8 cycles, % . | Estimated PFS at 18 months, % . | ||||
|---|---|---|---|---|---|---|---|
| ≥ PR . | ≥ VGPR . | CR/nCR . | ≥ PR . | ≥ VGPR . | CR/nCR . | ||
| RVD6 | 75 | 11 | 6 | 96 | 53 | 23 | 75 |
| RVDD | 96 | 57 | 29 | 95 | 65 | 35 | 82 |
Includes all patients (phase 1/2). Best-response rates for RVD after a median of 10 cycles: > PR, 100%; > VGPR, 67%; and CR/nCR, 39%. Best-response rates for RVDD after a median of 4.5 cycles: > PR, 96%; > VGPR, 67%; and CR/nCR, 39%.